Recipient: Dr Susan Heatley
Institute: South Australian Health & Medical Research Institute
Funding: $398,146 July 2016 to June 2022
Patients diagnosed with specific subsets of acute lymphoblastic leukaemia (ALL) are sadly at high risk of relapse. Due to the toxic effects caused by non-targeted therapies, treatment options are limited.
Behind the Science: Dr Susan Heatley
Research carried out by Dr Heatley has shown that a substantial proportion of treatment failures in ALL patients are attributable to specific mutations, referred to as Ph-like ALL subtype, which are prevalent among adolescents.
Thanks to funding by The Kids’ Cancer Project, Dr Heatley will further study the genetic changes underpinning Ph-like ALL. Through better understanding of what drives the disease at a genetic level, researchers will be able to establish effective treatment options with a personalised medicine approach.